B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
B7-H3
CD276
DS-7300
MGC018
NSCLC
enoblituzumab
immunotherapy
obrindatamab
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
16 Dec 2022
16 Dec 2022
Historique:
received:
31
10
2022
revised:
03
12
2022
accepted:
15
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
The striking clinical outcomes of antibody-based immunotherapy, through the inhibitors of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death protein-1 (PD-1) and its ligand (PD-L1) axis, have driven research aimed at identifying further clinically relevant tumor antigens that can serve as targets in solid tumors. B7 homolog 3 protein (B7-H3, also known as CD276) is a member of the B7 family overexpressed in tumor tissues, including non-small cell lung cancer (NSCLC), while showing limited expression in normal tissues, becoming an attractive and promising target for cancer immunotherapy. B7-H3 expression in tumors has been demonstrated to be associated with poor prognosis. In addition to its role in immune modulation, B7-H3 also promotes pro-tumorigenic functions such as tumor migration, invasion, metastases, resistance, and metabolism. In this review, we will provide an overview of this newly characterized immune checkpoint molecule and its development in the management of metastatic NSCLC.
Identifiants
pubmed: 36555714
pii: ijms232416077
doi: 10.3390/ijms232416077
pmc: PMC9788608
pii:
doi:
Substances chimiques
B7 Antigens
0
B7-H1 Antigen
0
Antibodies
0
CD276 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Urol. 2011 Sep;186(3):1093-9
pubmed: 21784485
Onco Targets Ther. 2018 Aug 10;11:4693-4700
pubmed: 30127617
Int J Data Min Bioinform. 2012;6(3):292-303
pubmed: 23155763
Clin Cancer Res. 2018 Jun 1;24(11):2653-2664
pubmed: 29530936
J Clin Oncol. 2020 May 10;38(14):1608-1632
pubmed: 31990617
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Clin Cancer Res. 2021 Mar 1;27(5):1227-1235
pubmed: 33051306
Chest. 2007 Sep;132(3 Suppl):29S-55S
pubmed: 17873159
Lung Cancer. 2017 Jan;103:44-51
pubmed: 28024695
Semin Oncol. 2014 Oct;41(5):653-60
pubmed: 25440609
Nat Immunol. 2003 Sep;4(9):899-906
pubmed: 12925852
Front Immunol. 2021 Jul 19;12:701006
pubmed: 34349762
JAMA Oncol. 2022 Dec 1;8(12):1830-1839
pubmed: 36264554
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10277-8
pubmed: 18650376
J Clin Pathol. 2019 Jan;72(1):38-45
pubmed: 30279174
Open Med (Wars). 2019 Nov 07;14:805-812
pubmed: 31737785
Immunol Today. 1989 Mar;10(3):92-9
pubmed: 2525910
Trends Cancer. 2018 Jun;4(6):401-404
pubmed: 29860983
Clin Cancer Res. 2017 Sep 1;23(17):5202-5209
pubmed: 28539467
Eur J Cancer. 2020 Jul;133:74-85
pubmed: 32447027
Front Pharmacol. 2020 Jul 30;11:1089
pubmed: 32848731
Clin Lung Cancer. 2013 Mar;14(2):157-63
pubmed: 22868219
Oncotarget. 2015 Feb 20;6(5):3452-61
pubmed: 25609202
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35414591
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Lung Cancer. 2009 Nov;66(2):245-9
pubmed: 19269710
World J Surg Oncol. 2022 May 20;20(1):159
pubmed: 35590371
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Oncotarget. 2017 Nov 08;8(68):112584-112597
pubmed: 29348848
Cancers (Basel). 2018 Nov 30;10(12):
pubmed: 30513627
Clin Cancer Res. 2012 Jul 15;18(14):3834-45
pubmed: 22615450